***Supplemental Material***

**Dronedarone for the Treatment of Atrial Fibrillation with Concomitant Heart Failure with Preserved and Mildly Reduced Ejection Fraction: *Post-Hoc* Analysis of the ATHENA Trial**

Muthiah Vaduganathan, MD MPH1; Jonathan P. Piccini, MD, MHS2; A. John Camm, MD3; Harry J.G.M. Crijns, MD PhD4; Stefan D. Anker, MD PhD5; Javed Butler, MD MPH MBA6; John Stewart, MSc7; Rogelio Braceras, MD8; Alessandro P.-A. Albuquerque, MD MSc PhD8;

Mattias Wieloch, MD PhD9,10; Stefan H. Hohnloser, MD11

**Supplemental Figure 1. Kaplan Meier Analysis for Death or Cardiovascular (CV) Hospitalization in Placebo-Treated Patients in ATHENA**

Abbreviations: HF = heart failure; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF / LVD = heart failure with reduced ejection fraction or left ventricular dysfunction

****

**Supplemental Figure 2. Sensitivity Analysis with Less Stringent Criteria to Define Heart Failure with Preserved and Mildly Reduced Ejection Fraction (HFpEF/HFmrEF)**

This sensitivity analysis evaluated the 2,353 individuals who met less stringent criteria for HFpEF/HFmrEF by removing requirement for structural heart disease.

****